Homocysteine and vascular disease

Lancet

Volumn 354, Issue 9176, 1999, Pages 407-413

  Hankey, Graeme J ^a,b   Eikelboom, John W ^c  

^a ROYAL PERTH HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FOLIC ACID; HOMOCYSTEINE;

AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; DIET SUPPLEMENTATION; HOMOCYSTINURIA; HUMAN; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; THROMBOSIS; VASCULAR DISEASE;

EID: 0033620779     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)11058-9     Document Type: Review

References (66)

1. Whisnant J.P. Modeling of risk factors for ischemic stroke: the Willis lecture. Stroke. 28:1997;1839-1843.
2. McCully K.S. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol. 56:1969;111-128.
3. Ueland P.M. Homocysteine species as components of plasma redox thiol status. Clin Chem. 41:1995;340-342.
4. Dudman N.P., Wilcken D.E., Wang J., Lynch J.F., Macey D., Lundberg P. Disordered methionine/homocysteine metabolism in premature vascular disease: its occurrence, cofactor therapy, and enzymology. Arterioscler Thomb Vasc Biol. 12:1993;1253-1260.
5. Still R.A., McDowell I.F. Clinical implications of plasma homocysteine measurement in cardiovascular disease. J Clin Pathol. 51:1998;183-188.
6. Refsum H., Fiskerstrand T., Guttormsen A.B., Ueland P.M. Assessment of homocysteine status. J Inherit Metab Dis. 20:1997;286-294.
7. Finkelstein J.D. The metabolism of homocysteine: pathways and regulation. Eur J Pediatr. 157(2):1998;40-44.
8. Mudd S.H., Skovby F., Levy H.L.et al. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet. 37:1985;1-31.
9. Kraus J.P. Biochemistry and molecular genetics of cystathionine beta-synthase deficiency. Eur J Pediatr. 157(2):1998;50-53.
10. Ogier de Baulny H., Gerard M., Saudubray J.M., Zittoun J. Remethylation defects: guidelines for clinical diagnosis and treatment. Eur J Pediatr. 157(2):1998;77-83.
11. Kang S.S., Zhou J., Wong P.W.K., Kowalisyn J., Strokosch G. Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet. 43:1988;414-421.
12. Frosst P., Blom H.J., Milos R.et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 10:1995;111-113.
13. Malinow M.R., Nieto F.J., Kruger W.D.et al. The effects of folic acid supplementation on plasma total homocysteine are modulated by multivitamin use and methylenetetrahydrofolate reductase genotypes. Arterioscler Thromb Vasc Biol. 17:1997;1157-1162.
14. Selhub J., Jacques P.F., Wilson P.W., Rush D., Rosenberg I.H. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA. 270:1993;2693-2698.
15. Kang S.S., Wong P.W.K., Norusis M. Homocysteinaemia due to folate deficiency. Metabolism. 36:1987;458-462.
16. Bostom A.G., Lathrop L. Homocysteinemia in end-stage renal disease: prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int. 52:1997;10-20.
17. Savage D.G., Lindenbaum J., Stabler S.P., Allen R.H. Sensitivity of serum methylmalonic acid and total homocysteine determinants for diagnosing cobalamin and folate deficiencies. Am J Med. 96:1994;239-246.
18. Frantzen F., Faaren A.L., Alfheim I., Nordhei A.K. Enzyme conversion immunoassay for determining total homocysteine in plasma or serum. Clin Chem. 44:1998;311-316.
19. Guttormsen A.B., Scheede J., Fiskerstrand T., Ueland P.M., Refsum H.M. Plasma concentrations of homocysteine and other aminothiol compounds are related to food intake in healthy human subjects. J Nutr. 124:1994;1934-1941.
20. Graham I.M., Daly L.E., Refsum H.M.et al. Plasma homocysteine as a risk factor for vascular disease: the European Concerted Action Project. JAMA. 277:1997;1775-1781.
21. Garg U.C., Zheng Z.J., Folsom A.R.et al. Short-term and long-term variability of plasma homocysteine measurement. Clin Chem. 43:1997;141-145.
22. Nygard O., Refsum H., Ueland P.M., Vollset S.E. Major lifestyle determinants of plasma total homocysteine distribution: the Hordaland Homocysteine Study. Am J Clin Nutr. 67:1998;263-270.
23. Lindgren A., Brattstrom L., Norrving B., Hultberg B., Anderson A., Johansson B.B. Plasma homocysteine in the acute and convalescent phases of stroke. Stroke. 26:1995;796-800.
24. Egerton W., Silberberg J., Crooks R., Ray C., Xie L., Dudman N. Serial measures of plasma homocyst(e)ine after acute myocardial infarction. Am J Cardiol. 77:1996;759-761.
25. Rasmussen K., Moller J., Lungbak M.et al. Age- and gender-specific reference intervals for total homocysteine and methylmalonic acid in plasma before and after vitamin supplementation. Clin Chem. 42:1996;630-636.
26. Dudman N.P.B., Guo X.W., Crooks R.et al. Assay of plasma homocysteine: light sensitivity of the fluorescent 7-benzo-2-oxa-1,3-diazo-4-sulfonic acid derivative, and use of appropriate calibrators. Clin Chem. 42:1996;2028-2032.
27. McCully K.S. Homocysteine and vascular disease. Nat Med. 2:1996;386-389.
28. Malinow M.R., Duell P.B., Hess D.L.et al. Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. N Engl J Med. 338:1998;1009-1015.
29. Wilcken D.E.L., Wilcken B. The pathogenesis of coronary artery disease: a possible role for methionine metabolism. J Clin Invest. 57:1976;1079-1082.
30. Stampfer M.J., Malinow R., Willett W.C.et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA. 268:1992;877-881.
31. Wald N.J., Watt H.C., Law M.R., Weir D.G., McPartlin J., Scott J.M. Homocysteine and ischemic heart disease: results of a prospective study with implications regarding prevention. Arch Intern Med. 158:1998;862-867.
32. Arnesen E., Refsum H., Bonaa K.J., Ueland P.M., Forde O.H., Nordrehaug J.E. Serum total homocysteine and coronary heart disease. Int J Epidemiol. 24:1995;704-709.
33. Pery I.J., Refsum H., Morris R.W., Ebrahim S.B., Ueland P.M., Shaper A.G. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet. 346:1995;1395-1398.
34. Nygard O., Nordrehaug J.E., Refsum H., Ueland P.M., Farstad M., Vollset S.E. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 337:1997;230-236.
35. 6 and risk of myocardial infarction in US physicians. J Am Coll Nutr. 15:1996;136-143.
36. Verhoef P., Hennekens C.H., Allen R.H., Stabler S.P., Willett W.C., Stampfer M.J. Plasma total homocysteine and risk of angina pectoris with subsequent coronary artery bypass surgery. Am J Cardiol. 79:1997;799-801.
37. Verhoef P., Hennekens C.H., Malinow M.R., Kok F.J., Willett W.C., Stampfer M.J. A prospective study of plasma homocyst(e)ine and risk of ischemic stroke. Stroke. 25:1994;1924-1930.
38. Evans R.W., Shaten J., Hempel J.D., Cutler J.A., Kuller L.H. Homocyst(e)ine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial. Arterioscler Thromb Vasc Biol. 17:1997;1947-1953.
39. Alfthan G., Pekkanen J., Jauhiainen M.et al. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis. 106:1994;9-19.
40. Folsom A.R., Nieto J., McGovern P.G.et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 98:1998;204-210.
41. Boushey C.J., Beresford S.A.A., Omenn G.S., Motulsky A.G. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intake. JAMA. 274:1995;1049-1057.
42. Hopkins P.N., Wu L.L., Hunt S.C.et al. Higher plasma homocysteine and increased susceptibility to adverse effects of low folate in early familial coronary artery disease. Arterioscler Thromb Vasc Biol. 15:1995;1314-1320.
43. 6, pyridoxal phosphate, and folate. Am J Cardiol. 75:1995;1107-1111.
44. Robinson K., Meyer E.L., Miller D.P.et al. Hyperhomocysteinaemia and low pyridoxal phosphate: common and independent reversible risk factors for coronary artery disease. Circulation. 92:1995;2825-2830.
45. Malinow M.R., Ducimetiere P., Luc G.et al. Plasma homocyst(e)ine levels and graded risk for myocardial infarction: findings in two populations at contrasting risk for coronary heart disease. Atherosclerosis. 26:1996;27-34.
46. Markus H.S., Nadira A., Swaminathan R., Sankaralingam A., Molloy J., Powell J. A common polymorphism in the methylenetetrahydrofolate reductase gene, homocysteine, and ischaemic cerebrovascular disease. Stroke. 28:1997;1739-1743.
47. Malinow R.M., Nieto J., Szklo M., Chambles L.E., Bond G. Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults: the Atherosclerosis Risk in Communities study. Circulation. 87:1993;1107-1113.
48. Selhub J., Jacques P.F., Bostom A.G., D'Agostino R.B., Wilson P.W.F., Belanger A.J.S. Association between plasma homocysteine concentrations and extracranial carotid-artery disease. N Engl J Med. 332:1995;286-291.
49. Verhoef P., Kok F.J., Kruyssen D.A.C.M.et al. Plasma total homocysteine, B vitamins, and risk of coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 17:1997;989-995.
50. Montalescot G., Ankri A., Chadefaux-Vekemans B.et al. Plasma homocysteine and the extent of atherosclerosis in patients with coronary artery disease. Int J Cardiol. 60:1997;295-300.
51. Konnecky N., Malinow R., Tunick P.A.et al. Correlation between plasma homocyst(e)ine and aortic atherosclerosis. Am Heart J. 133:1997;534-540.
52. van den Berg M., Stehouver C.D.A., Bierdrager E.et al. Plasma homocysteine and severity of atherosclerosis in young adults with lower-limb atherosclerotic disease. Arterioscler Thromb Vasc Biol. 16:1996;165-171.
53. Brattstrom L., Wilcken D.E.L., Ohrvik J., Brudin L. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease. Circulation. 98:1998;2520-2526.
54. Blom H.J. Mutated 5,10-methylenetetrahydrofolate reductase and moderate hyperhomocysteinaemia. Eur J Pediatr. 157(2):1998;131-134.
55. Ray J.G. Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. Arch Intern Med. 158:1998;2101-2116.
56. Ridker P.M., Hennekens C.H., Selhub J., Miletich J.P., Malinow M.R., Stampfer M.J. Interrelation of hyperhomocyst(e)inaemia, factor V Leiden, and risk of future venous thromboembolism. Circulation. 95:1997;1777-1782.
57. Petri M., Roubenoff R., Dallal G.E., Nadeau M.R., Selhub J., Rosenberg I.H. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet. 348:1996;1120-1124.
58. Nygard O., Vollset S.E., Refsum H.et al. Total plasma homocysteine and cardiovascular risk profile. JAMA. 224:1995;1526-1533.
59. Welch G.N., Upchurch G. Jr., Loscalzo J. Hyperhomocyst(e)inaemia and atherothrombosis. Ann N Y Acad Sci. 811:1997;48-58.
60. Oakley G.P. Eat right and take a multivitamin. N Engl J Med. 338:1998;1060-1061.
61. den Heijer M., Brouwer I.A., Bos G.M.J.et al. Vitamin supplementation reduces blood homocysteine levels: a controlled trial in patients with venous thrombosis and healthy volunteers. Arterioscler Thromb Vasc Biol. 18:1998;356-361.
62. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. BMJ. 316:1998;894-898.
63. Savage D.G., Lindenbaum J. Folate-cobalamin interactions. Bailey L.B. Folate in Health and Disease. 1995;237-285 Marcel Dekker, New York.
64. Wilcken D.E.L., Wilcken B. The natural history of vascular disease in homocystinuria and the effects of treatment. J Inher Metab Dis. 20:1997;295-300.
65. Peterson J.C., Spence J.D. Vitamins and progression of atherosclerosis in hyperhomocyst(e)inaemia. Lancet. 351:1998;263.
66. Anon. Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects. MMWR 1992; 41: (RR-14): 1-7.